odanacatib
Sign in to saveAlso known as MK-0822
Odanacatib (INN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.
Wikidata facts
- Mass
- 525.170926
Show 4 more facts
- chemical formula
- C₂₅H₂₇F₄N₃O₃S
- isomeric SMILES
- CC(C)(C[C@@H](C(=O)NC1(CC1)C#N)N[C@@H](C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
- canonical SMILES
- CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
- Commons category
- Odanacatib
via Wikidata · CC0
~2 min read
Article
1 sectionsContents
- References
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443444475 | IUPAC_name = N-(1-Cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide | image = Odanacatib corrected.svg | image_class = skin-invert-image | width = 300
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Development terminated | routes_of_administration = By mouth
Available in 8 languages
via Wikidata sitelinks · CC0